Spending on postapproval drug safety.
Repository Usage Stats
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding safety efforts. Mean spending on postapproval safety per company in 2003 was 56 million dollars (0.3 percent of sales). Assuming a constant safety-to-sales ratio, we estimated that total spending on postapproval safety by the top twenty drug manufacturers was 800 million dollars in 2003. We also examined, using regression analysis, the relationship between the number of safety personnel and the number of initial adverse-event reports. This study offers information for the debate on proposed changes to safety surveillance.
SubjectCosts and Cost Analysis
Product Surveillance, Postmarketing
Published Version (Please cite this version)10.1377/hlthaff.25.2.429
Publication InfoRidley, David B; Kramer, Judith M; Tilson, Hugh H; Grabowski, Henry G; & Schulman, Kevin A (2006). Spending on postapproval drug safety. Health Aff (Millwood), 25(2). pp. 429-436. 10.1377/hlthaff.25.2.429. Retrieved from https://hdl.handle.net/10161/6397.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives
Professor Emeritus of Medicine
· Studying methods to facilitate the uptake of evidence-based treatment recommendations. · Optimizing the use of drugs, devices, and biological products in clinical practice. · Studying methods of risk management for therapeutic products
Professor of the Practice of Business Adminstration
David Ridley is the Faculty Director of Health Sector Management at Duke University’s Fuqua School of Business. In his research, he examines innovation and pricing in health care. David was the lead author of the paper proposing the priority review voucher program which became law in 2007 and created
Adjunct Professor in the Department of Medicine
Kevin A. Schulman, MD, MBA, is a professor of medicine and the Gregory Mario and Jeremy Mario Professor of Business Administration (2010 - 2016) at Duke University. He is a visiting professor of business administration at Harvard Business School. He holds several leadership appointments at Duke. He is an associate director of the Duke Clinical Research Institute in the School of Medicine, the country's largest academic clinical research organization. In Duke's Fuqua School of Business, he s
This author no longer has a Scholars@Duke profile, so the information shown here reflects their Duke status at the time this item was deposited.
Alphabetical list of authors with Scholars@Duke profiles.